Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
November 09, 2017 07:30 ET
|
Avenue Therapeutics
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
September 27, 2017 08:00 ET
|
Avenue Therapeutics
NEW YORK, Sept. 27, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that the first patient has been dosed in...
Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer)
August 15, 2017 08:00 ET
|
Avenue Therapeutics
NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced the appointment of Joseph Vazzano as Vice...
Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
August 11, 2017 07:30 ET
|
Avenue Therapeutics
NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate...
Avenue Therapeutics Completes Initial Public Offering
June 30, 2017 11:30 ET
|
Avenue Therapeutics
NEW YORK, June 30, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today that it has completed its initial...
Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock
June 26, 2017 19:30 ET
|
Avenue Therapeutics
NEW YORK, June 26, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) company, announced today the pricing of its initial public offering of...
Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
May 19, 2017 08:00 ET
|
Avenue Therapeutics
NEW YORK, May 19, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notice of Allowance has now been received from the...
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
January 03, 2017 08:00 ET
|
Avenue Therapeutics
NEW YORK, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that Notices of Allowance have now been received from the...
Avenue Therapeutics Files to Become a Public Reporting Company
December 30, 2015 08:00 ET
|
Avenue Therapeutics
NEW YORK, Dec. 30, 2015 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (“Avenue”), a Fortress Biotech, Inc. (NASDAQ:FBIO) Company, announced that it filed a registration statement on Form 10 with...